Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Ironwood Buys AstraZeneca's Zurampic As Ideal Linzess Complement

Executive Summary

What was AstraZeneca's trash is now Ironwood's treasure, as it pays $100m up front, along with milestones and royalties, to acquire gout drug approved in December, but not yet launched.


Related Content

AZ's Gout Drug Gets FDA Go-Ahead With Safety Caveats
FDA: AZ/Ardea Gout Drug Modest Efficacy, Safety Concerns
AZ's lesinurad misses in Phase III gout at lower dose
AstraZeneca looks to combos after effective ex-Ardea drug shows serious adverse effects
AstraZeneca to pay $1.26 billion for Ardea and its gout product


Related Companies